Burrill & Company Forms Joint Bio Investment Fund With Korea - Bio Korea 2009
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Korean pharmaceutical outfits and investors should focus more on burgeoning biotech companies and take advantage of the Korean government's increasing interest in funding the industry, Burrill & Company CEO Steven Burrill said at the Bio Korea 2009 meeting in Seoul Sept. 16
You may also be interested in...
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1
Green Cross To Focus On Biobetters As Korean Biosimilar Space Gets Crowded: Bio Korea Conference
SEOUL - Green Cross will turn its attention to "biobetters" in coming years such as its biobetter of Roche's oncology agent Herceptin (trastuzumab) being pursued now, Green Cross CEO Rhee Byung-Geon said during the Bio Korea 2010 conference in Seoul Sept. 1
Korean Government Announces Joint Fund To Beef Up Local Pharma Industry
SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs